MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
-0.030
-1.69%
After Hours: 1.740 0 0.00% 19:47 05/13 EDT
OPEN
1.860
PREV CLOSE
1.770
HIGH
1.890
LOW
1.680
VOLUME
398.90K
TURNOVER
--
52 WEEK HIGH
8.59
52 WEEK LOW
1.250
MARKET CAP
40.75M
P/E (TTM)
-0.8549
1D
5D
1M
3M
1Y
5Y
Catabasis Pharmaceuticals EPS misses by $7.42
Catabasis Pharmaceuticals (CATB): Q1 GAAP EPS of -$7.60 misses by $7.42.As of March 31, 2021, Catabasis had cash, cash equivalents and short-term investments of $146.9 million, compared to $44.9 million
Seekingalpha · 9h ago
Catabasis Pharmaceuticals Q1 EPS $(7.60) Down From $(0.50) YoY
Catabasis Pharmaceuticals (NASDAQ:CATB) reported quarterly losses of $(7.60) per share. This is a 1420 percent decrease over losses of $(0.50) per share from the same period last year.
Benzinga · 9h ago
BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $7.60
reuters.com · 10h ago
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021
 
Benzinga · 1d ago
--Ladenburg Thalmann Starts Catabasis Pharmaceuticals at Buy With $6 Price Target
MT Newswires · 1d ago
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to ...
Benzinga · 2d ago
Analyst Explains Why They Upgraded Their Rating on Catabasis Pharmaceuticals (CATB)
Oppenheimer analyst Hartaj Singh upgraded Catabasis Pharmaceuticals (CATB) to Buy yesterday and set a price target of $5.00. The company's shares closed
SmarterAnalyst · 03/19 02:50
Catabasis Pharmaceuticals (CATB) Receives a Rating Update from a Top Analyst
SmarterAnalyst · 03/12 11:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CATB. Analyze the recent business situations of Catabasis Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CATB stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 79
Institutional Holdings: 9.68M
% Owned: 41.32%
Shares Outstanding: 23.42M
TypeInstitutionsShares
Increased
16
976.04K
New
25
2.36M
Decreased
14
524.91K
Sold Out
14
4.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.35%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Co-Founder/Director
Jill Milne
Chief Financial Officer
Noah Clauser
Senior Vice President/General Counsel
Benjamin Harshbarger
Chief Scientific Officer
Andrew Nichols
Other
Edward Hibben
Other
Andrew Komjathy
Director
Fred Callori
Director
Jonathan Violin
Independent Director
Burt Adelman
Independent Director
Joanne Beck
Independent Director
Hugh Cole
Independent Director
Michael Kishbauch
Independent Director
Gregg Lapointe
No Data
About CATB
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to edasalonexent, the Company has developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. The Company’s Safely Metabolized and Rationally Targeted (SMART) is a linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Webull offers kinds of Catabasis Pharmaceuticals Inc stock information, including NASDAQ:CATB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CATB stock methods without spending real money on the virtual paper trading platform.